ROBB GARY CHARLES (Chief Business Officer) sold 20.1% of their position (10K shares) of CORCEPT THERAPEUTICS INC on the open market
Open‑market sale worth $1.16M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/18/2026ACC: 0001193125-26-355560
Officer· Chief Business Officer
Since Mar 2026
-10.13K
Net shares
Net seller
$1.16M
Total sold
1
Open market trades
0B · 1S
2
Total transactions
10.13K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−125.00
Price / share
—
Trade value
—
% of position
0.9%
8/17/2026
13.55K→13.43K
Common Stock
Indirect
Shares
−10K
Price / share
$116.26
Trade value
$1.16M
% of position
20.1%
8/17/2026
49.72K→39.72K
Total
Net shares
−10.13K
Net value
-$1.16M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/17/2026 | G · Gift | −125.00 | — | — | 0.9% | 13.55K | 13.43K |
| Common Stock Indirect | 8/17/2026 | S · Sale | −10K | $116.26 | $1.16M | 20.1% | 49.72K | 39.72K |
| Total | −10.13K | -$1.16M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned15.57K
Common Stock
IndirectShares owned15.57K
Total
31.14K indirect31.14K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 15.57K | Indirect |
| Common Stock | 15.57K | Indirect |
| Total | 31.14K | 31.14K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported